Sign up
Pharma Capital

Avalon GloboCare expects to be added to Russell 3000 Index

The Russell 3000 Index is a market-capitalization-weighted equity index that gives investors exposure to the entire US stock market
markets
The New Jersey-based biotech should be added to the massive index after the markets close on June 28

Avalon GloboCare Corp (NASDAQ:AVCO), a developer of cell-based technologies and therapeutics, announced Tuesday that it expects to be added to the Russell 3000 Index.

The Freehold, New Jersey-based company said it should be added to the massive index after the markets close on June 28.

The Russell 3000 Index is a market-capitalization-weighted equity index that gives investors exposure to the entire US stock market. The index tracks the performance of the 3,000 largest US-traded stocks, which represent about 98% of all US incorporated equity securities. 

READ: Avalon GloboCare's stock soars after positive study on first saliva-based biomarker as a diagnostic for oral cancer

"We look forward to our inclusion in the Russell 3000 Index, which we believe reflects our continued growth and the progress we are making at Avalon," said CEO Dr David Jin. "Inclusion in the Russell 3000 Index is expected to benefit our company and shareholders by elevating our exposure within the global investment community."

Avalon is currently in the Russell Microcap Index, a capitalization-weighted index of almost 1,550 small-cap and micro-cap stocks, and will remain on that index for one year.

The company specializes in developing cell-based technologies but is also involved in the management of stem cell banks and clinical laboratories. It also develops proprietary diagnostic and therapeutic products leveraging exosome technology and markets proprietary exosome isolation systems and related products to hospitals.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

1556543955_patrick.graham.jpg


Register here to be notified of future AVCO Company articles
View full AVCO profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.